

Yoshihiro Tadori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7062517/publications.pdf>

Version: 2024-02-01

9
papers

321
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

466
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 591-601.	1.8	12
2	Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 445-453.	1.8	27
3	Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 74-80.	2.0	28
4	An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 84-94.	1.8	20
5	Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 701-712.	1.8	8
6	Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 692-700.	1.8	50
7	Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. <i>Child Psychiatry and Human Development</i> , 2017, 48, 796-806.	1.9	62
8	Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors. <i>European Journal of Pharmacology</i> , 2011, 666, 43-52.	3.5	58
9	Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912. <i>European Journal of Pharmacology</i> , 2007, 574, 103-111.	3.5	55